Testing may help identify:

  • How your cancer may grow or behave
  • Available treatment options for your unique cancer
  • Information regarding your family's risk for developing certain cancers (depending on the type of test performed)

That’s why you should talk to your doctor about a genetic test as early as possible after your diagnosis of metastatic castration-resistant prostate cancer. Certain genetic tests can help determine if you may be eligible for treatment with LYNPARZA.

Find out how genetic testing for your metastatic prostate cancer can help identify HRR gene mutations

Homologous recombination deficiency, or HRD, is an important biomarker of metastatic prostate cancer. An HRD test is a type of genomic test that assesses the DNA profile of your tumor including different mutations, such as mutations in the BRCA1 or BRCA2 genes, and other changes to your DNA.

BRCA and other HRR mutations can be acquired or inherited. What is the difference between acquired and inherited mutations and how are they tested?

About 1 in 10 people with metastatic castration-resistant prostate cancer has a BRCA mutation

 

Acquired, also called somatic

  • Not present from birth, but happens at some point during a person's life
  • Not present in every cell
  • Testing can be done using a tumor tissue sample from a biopsy, or by a plasma sample

Inherited, also called germline

  • Passed down from a parent
  • Found in every cell in the body, including tumor cells
  • Testing can be done using a tumor tissue sample from a biopsy, or by a blood or plasma sample

Your doctor can perform a test to help determine if you may be eligible for treatment with LYNPARZA

Ask Your Doctor About Getting Tested